CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today
CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today
Amy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapiesDae Gon Ha, Ph.D., appointed
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation,
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation,
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation,
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation,
Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved Utebzi™ (tebipenem
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation,
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation,
Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseasesAppointment strengthens Spero’s clinical leadership team as the Company advances SP001, a Phase 2-ready
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize IBI355 (Spero R&D code: SP001)Innovent will receive an
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is
LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated
